Published on June 18, 2024, 4:04 am

In the rapidly evolving digitalization landscape accelerated by the pandemic, digital health has taken center stage in societies with increasing connectivity needs. A recent report by Capgemini’s Research Institute reveals that the majority (63%) of healthcare organizations, including biopharmaceutical and medical technology firms, already have connected health products on the market or in development. Despite varying stages of product development, these organizations anticipate that connected health solutions will contribute over a fifth of their total revenues in the next five years. However, the lack of essential data capabilities could pose challenges to this goal.

The report underscores that three out of five healthcare organizations are crafting a roadmap to integrate Generative AI into their operations, with over half already experimenting with this technology to engage with patients and healthcare professionals. While about half of these organizations believe their efforts in connected health have intensified, most acknowledge a need for stronger data management capabilities. The research confirms a general dearth of common frameworks, standards, and tools for data management related to connected health despite a more refined strategy and extensive planning compared to three years ago.

Furthermore, there has been a sixfold increase in biopharmaceutical organizations with market-ready connected health products since 2021. Although preventive care and physical exercise remain top priorities for many biopharma companies, attention is shifting towards previously neglected areas like diagnosis and monitoring. Oncology, immunology, and cardiology emerge as key focus areas for most biopharma enterprises, while emerging fields such as mental health, diabetes, obesity, and dermatology have shown significant growth since 2021.

Connected health remains a top priority for medical technology firms as well. Three out of four admit to having connected health products either in the market or under development; digital health solutions and wearable devices are at the forefront of their interests.

The report highlights significant progress among biopharmaceutical companies in leveraging AI, machine learning (ML), and cloud technologies over the past three years. Those utilizing AI for real-time predictive analysis of connected healthcare products nearly doubled from 24% to 46% since 2021. Additionally, more than two-fifths (42%) have adopted cloud platforms for integrating data from diverse sources.

Despite advancements, only a minority of surveyed healthcare organizations mentioned possessing adequate technical skills such as AR/VR and Generative AI. To bridge this gap, nearly two-thirds prefer enhancing their current workforce’s skills while 56% consider hiring new talent.

Generative AI shows promise across the entire healthcare value chain spanning research, clinical development, operations, regulation compliance marketing post-launch operations among others. Over half of organizations are currently testing Generative AI for interactions with patients and healthcare professionals besides exploring applications like synthetic data generation; existing data analysis automation regulatory documentation supplier management product design clinical trial site identification amongst others.

Although connected health presents new industry opportunities; establishing a clear vision tailored to specific healthcare needs is crucial for measurable impact according to the report. Investing in scalable secure compliant data infrastructure enhanced collaboration with ecosystem stakeholders can yield tangible value for all involved parties.


Comments are closed.